Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
Jeffrey A. Meyerhardt(CancerCare), Charles S. Fuchs(University of Southern California), Ann Michelini(Dana-Farber Cancer Institute), Joseph P. Eder(Yale Cancer Center), Robert J. Mayer(Applied Natural Sciences), David P. Ryan(East Carolina University), Shuji Ogino(Broad Institute), Kate Kinsella(Dana-Farber Cancer Institute), Jeffrey W. Clark(Massachusetts General Hospital), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Jeffrey G. Supko(Harvard University), Peter C. Enzinger(Dana-Farber Cancer Institute), Clinton F. Stewart(St. Jude Children's Research Hospital), Craig C. Earle(Canadian Partnership Against Cancer), Ferdinando D’Amato(Harvard University), Janet Dancey(Ontario Institute for Cancer Research)
Cited by 26
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k